Huntington's Disease is a disorder of the corpus striatum: Focus on Rhes (Ras homologue enriched in the striatum)

Srinivasa Subramaniam, Solomon H Snyder

Research output: Contribution to journalArticle

Abstract

Despite identification of the gene for huntingtin (Htt) as causal in Huntington's Disease (HD), explication of HD symptoms and selective damage to the corpus striatum has been elusive. The small G protein Rhes Ras homolog enriched in striatum, highly localized to the striatum, binds selectively to mutant Htt (mHtt) and enhances sumoylation of mHtt. Sumoylation disaggregates mHtt and augments its cytotoxicity. Thus, it appears likely that Rhes-mHtt interaction accounts in substantial part for the selective striatal neurotoxicity of HD with associated extrapyramidal symptomatology. Rhes also binds and activates mTOR, enhancing its influence on protein synthesis, and may be the principal determinant of striatal mTOR activation. In HD, sequestration of Rhes by mHtt may decrease its access to mTOR. The attendant loss of protein translational stimulation may explain the pronounced striatal atrophy of HD. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

Original languageEnglish (US)
Pages (from-to)1187-1192
Number of pages6
JournalNeuropharmacology
Volume60
Issue number7-8
DOIs
StatePublished - Jun 2011

Fingerprint

Corpus Striatum
Huntington Disease
Sumoylation
Neuropharmacology
Monomeric GTP-Binding Proteins
Atrophy
Proteins
Genes

Keywords

  • Atrophy
  • HAP
  • HIP
  • Huntington Disease
  • mTOR
  • mutant Huntingtin
  • Rhes
  • Striatum

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Huntington's Disease is a disorder of the corpus striatum : Focus on Rhes (Ras homologue enriched in the striatum). / Subramaniam, Srinivasa; Snyder, Solomon H.

In: Neuropharmacology, Vol. 60, No. 7-8, 06.2011, p. 1187-1192.

Research output: Contribution to journalArticle

@article{226acac3b0224c24a3e80509d16928fa,
title = "Huntington's Disease is a disorder of the corpus striatum: Focus on Rhes (Ras homologue enriched in the striatum)",
abstract = "Despite identification of the gene for huntingtin (Htt) as causal in Huntington's Disease (HD), explication of HD symptoms and selective damage to the corpus striatum has been elusive. The small G protein Rhes Ras homolog enriched in striatum, highly localized to the striatum, binds selectively to mutant Htt (mHtt) and enhances sumoylation of mHtt. Sumoylation disaggregates mHtt and augments its cytotoxicity. Thus, it appears likely that Rhes-mHtt interaction accounts in substantial part for the selective striatal neurotoxicity of HD with associated extrapyramidal symptomatology. Rhes also binds and activates mTOR, enhancing its influence on protein synthesis, and may be the principal determinant of striatal mTOR activation. In HD, sequestration of Rhes by mHtt may decrease its access to mTOR. The attendant loss of protein translational stimulation may explain the pronounced striatal atrophy of HD. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.",
keywords = "Atrophy, HAP, HIP, Huntington Disease, mTOR, mutant Huntingtin, Rhes, Striatum",
author = "Srinivasa Subramaniam and Snyder, {Solomon H}",
year = "2011",
month = "6",
doi = "10.1016/j.neuropharm.2010.10.025",
language = "English (US)",
volume = "60",
pages = "1187--1192",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "7-8",

}

TY - JOUR

T1 - Huntington's Disease is a disorder of the corpus striatum

T2 - Focus on Rhes (Ras homologue enriched in the striatum)

AU - Subramaniam, Srinivasa

AU - Snyder, Solomon H

PY - 2011/6

Y1 - 2011/6

N2 - Despite identification of the gene for huntingtin (Htt) as causal in Huntington's Disease (HD), explication of HD symptoms and selective damage to the corpus striatum has been elusive. The small G protein Rhes Ras homolog enriched in striatum, highly localized to the striatum, binds selectively to mutant Htt (mHtt) and enhances sumoylation of mHtt. Sumoylation disaggregates mHtt and augments its cytotoxicity. Thus, it appears likely that Rhes-mHtt interaction accounts in substantial part for the selective striatal neurotoxicity of HD with associated extrapyramidal symptomatology. Rhes also binds and activates mTOR, enhancing its influence on protein synthesis, and may be the principal determinant of striatal mTOR activation. In HD, sequestration of Rhes by mHtt may decrease its access to mTOR. The attendant loss of protein translational stimulation may explain the pronounced striatal atrophy of HD. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

AB - Despite identification of the gene for huntingtin (Htt) as causal in Huntington's Disease (HD), explication of HD symptoms and selective damage to the corpus striatum has been elusive. The small G protein Rhes Ras homolog enriched in striatum, highly localized to the striatum, binds selectively to mutant Htt (mHtt) and enhances sumoylation of mHtt. Sumoylation disaggregates mHtt and augments its cytotoxicity. Thus, it appears likely that Rhes-mHtt interaction accounts in substantial part for the selective striatal neurotoxicity of HD with associated extrapyramidal symptomatology. Rhes also binds and activates mTOR, enhancing its influence on protein synthesis, and may be the principal determinant of striatal mTOR activation. In HD, sequestration of Rhes by mHtt may decrease its access to mTOR. The attendant loss of protein translational stimulation may explain the pronounced striatal atrophy of HD. This article is part of a Special Issue entitled 'Trends in Neuropharmacology: In Memory of Erminio Costa'.

KW - Atrophy

KW - HAP

KW - HIP

KW - Huntington Disease

KW - mTOR

KW - mutant Huntingtin

KW - Rhes

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=79954590400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954590400&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2010.10.025

DO - 10.1016/j.neuropharm.2010.10.025

M3 - Article

C2 - 21044641

AN - SCOPUS:79954590400

VL - 60

SP - 1187

EP - 1192

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 7-8

ER -